Last reviewed · How we verify
Immune checkpoint inhibitors or docetaxel
Immune checkpoint inhibitors or docetaxel is a Combination therapy (checkpoint inhibitor + taxane chemotherapy) Small molecule drug developed by NovoCure GmbH. It is currently in Phase 3 development for Non-small cell lung cancer (Phase 3 trials).
This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells.
This is a combination approach using immune checkpoint inhibitors to enhance anti-tumor immunity and/or docetaxel chemotherapy to directly kill cancer cells. Used for Non-small cell lung cancer (Phase 3 trials).
At a glance
| Generic name | Immune checkpoint inhibitors or docetaxel |
|---|---|
| Sponsor | NovoCure GmbH |
| Drug class | Combination therapy (checkpoint inhibitor + taxane chemotherapy) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) block inhibitory signals that allow tumors to evade the immune system, thereby activating T-cell mediated anti-tumor responses. Docetaxel is a taxane chemotherapy agent that stabilizes microtubules and induces apoptosis in rapidly dividing cancer cells. The combination may provide synergistic benefit by combining direct cytotoxic effects with immune activation.
Approved indications
- Non-small cell lung cancer (Phase 3 trials)
Common side effects
- Fatigue
- Nausea and vomiting
- Neutropenia
- Immune-related adverse events (pneumonitis, colitis, hepatitis)
- Peripheral neuropathy
Key clinical trials
- ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) (PHASE3)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) (PHASE2)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (PHASE3)
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (PHASE3)
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immune checkpoint inhibitors or docetaxel CI brief — competitive landscape report
- Immune checkpoint inhibitors or docetaxel updates RSS · CI watch RSS
- NovoCure GmbH portfolio CI
Frequently asked questions about Immune checkpoint inhibitors or docetaxel
What is Immune checkpoint inhibitors or docetaxel?
How does Immune checkpoint inhibitors or docetaxel work?
What is Immune checkpoint inhibitors or docetaxel used for?
Who makes Immune checkpoint inhibitors or docetaxel?
What drug class is Immune checkpoint inhibitors or docetaxel in?
What development phase is Immune checkpoint inhibitors or docetaxel in?
What are the side effects of Immune checkpoint inhibitors or docetaxel?
Related
- Drug class: All Combination therapy (checkpoint inhibitor + taxane chemotherapy) drugs
- Manufacturer: NovoCure GmbH — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (Phase 3 trials)
- Compare: Immune checkpoint inhibitors or docetaxel vs similar drugs
- Pricing: Immune checkpoint inhibitors or docetaxel cost, discount & access